Американское общество гирудотерапии

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite

Research article published in Journal of cardiothoracic and vascular anesthesia (2020)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewРазработка лекарственных препаратовGoswami A et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Abstract

Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiac Surgical ProceduresCardiologyCardiopulmonary BypassChildHeparinHirudinsHumansPeptide FragmentsRecombinant Proteins

Резюме

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Почему это важно для гирудотерапии

This review examines the emerging role of bivalirudin as a primary anticoagulant in pediatric cardiac surgery, cardiopulmonary bypass, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology, providing an overview of its pharmacodynamics and monitoring methods. The abstract notes increasing interest in bivalirudin to circumvent heparin resistance and heparin-induced thrombocytopenia, while acknowledging it introduces additional challenges. The abstract makes no mention of hirudin, leeches, or any relationship to hirudotherapy, so no defensible ASH connection exists based on this source. As a review of existing literature, it does not generate new clinical data.

Цитирование

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite

Goswami A et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.